Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Liabilities from Discontinued Operations (2016 - 2018)

Historic Liabilities from Discontinued Operations for Soleno Therapeutics (SLNO) over the last 3 years, with Q3 2018 value amounting to $1.8 million.

  • Soleno Therapeutics' Liabilities from Discontinued Operations rose 144867.26% to $1.8 million in Q3 2018 from the same period last year, while for Sep 2018 it was $1.8 million, marking a year-over-year increase of 144867.26%. This contributed to the annual value of $225000.0 for FY2017, which is 868.51% down from last year.
  • Soleno Therapeutics' Liabilities from Discontinued Operations amounted to $1.8 million in Q3 2018, which was up 144867.26% from $1.0 million recorded in Q2 2018.
  • In the past 5 years, Soleno Therapeutics' Liabilities from Discontinued Operations registered a high of $1.8 million during Q3 2018, and its lowest value of $113000.0 during Q3 2017.
  • For the 3-year period, Soleno Therapeutics' Liabilities from Discontinued Operations averaged around $603342.9, with its median value being $246400.0 (2016).
  • In the last 5 years, Soleno Therapeutics' Liabilities from Discontinued Operations tumbled by 868.51% in 2017 and then surged by 144867.26% in 2018.
  • Soleno Therapeutics' Liabilities from Discontinued Operations (Quarter) stood at $246400.0 in 2016, then fell by 8.69% to $225000.0 in 2017, then skyrocketed by 677.78% to $1.8 million in 2018.
  • Its Liabilities from Discontinued Operations stands at $1.8 million for Q3 2018, versus $1.0 million for Q2 2018 and $625000.0 for Q1 2018.